CONTACTStaffCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2024 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
A lower percentage of HIV patients taking Reyataz experienced a rebound in viral levels compared with patients on other protease inhibitors, according to an announcement from Bristol-Myers Squibb, the manufacturer of Reyataz. The study of 419 patients found that 7% of those who switched to Reyataz experienced increasing viral levels, compared with 16% of patients who continued on other protease inhibitors. The company did not identify the other protease inhibitors. (AP)
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Meet all 37 of the queer women in this season's WNBA
April 17 2024 11:24 AM
Here are the 15 gayest travel destinations in the world: report
March 26 2024 9:23 AM
21+ steamy photos of Scotland’s finest gay men in Elska Glasgow
February 01 2024 10:07 PM
More Than 50 of Our Favorite LGBTQ+ Moms
May 12 2024 11:44 AM
Conjoined twins Lori Schappell and trans man George Schappell dead at 62
April 27 2024 6:13 PM
Latest Stories
Nancy Pelosi endorses Kamala Harris for president
July 22 2024 4:07 PM
Charli XCX declares Kamala Harris IS brat & our next President's campaign agrees
July 22 2024 3:08 PM
Pete Buttigieg roasts JD Vance and his gay tech bro billionaire
July 22 2024 1:42 PM
The AIDs pandemic can be ended by 2030, but governments must act: report
July 22 2024 1:01 PM
Conservatives' first attack on Kamala Harris: Pronouns and accessibility?
July 22 2024 12:45 PM
Advancing equality during Disability Pride Month
July 22 2024 11:30 AM